Metronidazole

— Advancing Strategy to Increase and Diversify Revenue through Ex-U.S. Commercialization — SAN DIEGO--(BUSINESS WIRE)-- $EVFM #BV --Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026. “Evofem continues to execute our strategy to increase revenues and to diversify and reduce risk in our revenue stream,” said Saundra Pelletier, CEO of Evofem. “A key component of this strategy is commercializing our FDA-approved sexual health products outside the U.S. through strategic alliances such as the ones we have forged for MENA and Sub-Saharan Africa. We look forward to non-dilutive capital from each of these markets in 2026.” Notable advances in 2026 to-date include: Expanded our global reach into Sub-Saharan Africa through a distribution agreement with Clovis Davis Pharmaceuticals for SOLOSEC ® (secnidazole) 2g oral granules . The Emirates Drug Establishment (EDE) review of the submissions for marketing approval of PHEXX ® (lactic acid, citric acid and potassium bitartrate) and SOLOSEC in the United Arab Emirates (UAE) is ongoing. The EDE issued favorable pricing certificates for PHEXX in late 2025. Advanced patient recruitment in an investigator-led, NIH-funded Phase 4 clinical trial evaluating the effectiveness and cost-effectiveness of SOLOSEC (single-dose, one time) versus metronidazole (twice daily for seven days) for the treatment of Trichomonas vaginalis in men and women. Study investigators hypothesize that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC group versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection. 1 First Quarter Financial Results For the three months ended March 31, 2026, net sales were $0.9 million, versus $0.8 million in the prior year period. The increase was primarily due to the higher WAC and more favorable gross-to-net ratio for both PHEXX and SOLOSEC and higher SOLOSEC ex-factory sales in the 2026 period, partially offset by lower ex-factory sales for PHEXX in the 2026 period following the exceptionally high level of PHEXX purchasing by wholesalers in December 2025 ahead of the January 2026 price increase. Total operating expenses were $5.5 million in the first quarter of 2026, compared to $6.1 million in the prior year period, after excluding a one-time $5.6 million reduction in research and development expense as a result of its successful settlement of a portion of its trade payables with multiple vendors. As a result, net loss was $5.5 million, or $(0.04) per basic and diluted share, in the first quarter of 2026. This compares to net income attributable to common stockholders of $1.0 million, or $0.01 per basic and $0.00 per fully diluted share, in the first quarter of 2025. About Evofem Evofem Biosciences is a San Diego-based pharmaceutical company commercializing two FDA-approved sexual and reproductive health products: PHEXX ® (lactic acid, citric acid, and potassium bitartrate) – the first and only hormone-free, on-demand prescription contraceptive vaginal gel. Visit phexx.com to learn more and for important safety information. SOLOSEC ® (secnidazole) 2g oral granules – an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. PHEXX ® and SOLOSEC ® are registered trademarks of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “could,” “estimate,” “expect,” “target,” “hypothesize,” “intend,” “potential,” “strategy,” “will,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to, Evofem’s expectations regarding the anticipated impact of COGS reduction initiatives, the commercialization of PHEXX and SOLOSEC, the timing and outcome of the EDE review of the submissions for PHEXX and SOLOSEC in the UAE, and the timing and magnitude of anticipated future commercial orders for and product launches in ex-U.S. markets. Forward-looking statements are based on current assumptions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements include, but are not limited to, limited cash resources, the Company’s ability to continue as a going concern, dependence on new capital or business development transactions to fund operations, potential delays in regulatory approvals, changes in market demand, manufacturing and supply chain risks, the nonrecurring nature of certain recent gains, risks related to the Company’s limited revenue base relative to operating expenses, and its reliance on third-party licensees and distributors for ex-U.S. commercialization, together with those that are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 11, 2026, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 filed with the SEC on May 15, 2026, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. Evofem undertakes no obligation to update or revise any forward-looking statement except as required by law, and investors are cautioned not to place undue reliance on such statements given the Company’s current liquidity position and evolving business conditions. Sources 1. National Institute of Allergy & Infectious Diseases (NIAID) of the National Institutes of Health. Award number R01AI183266 : Refining Trichomonas vaginalis treatment in women and men. EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands) As of March 31, 2026 December 31, 2025 Cash and cash equivalents $ 1,491 $ - Restricted cash and cash equivalents $ 888 $ 578 Trade accounts receivable, net $ 560 $ 12,480 Total current liabilities $ 78,752 $ 84,820 Total stockholders’ deficit $ (77,630 ) $ (74,336 ) Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit $ 7,442 $ 20,274 EVOFEM BIOSCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (In thousands, except share and per share data) Three Months Ended March 31, 2026 2025 Product sales, net $ 899 $ 845 Operating Expenses: Cost of goods sold 410 365 Amortization of intangible asset 75 223 Research and development, net 518 (5,035 ) Selling and marketing 2,093 2,600 General and administrative 2,372 2,365 Total operating expenses 5,468 518 Income (loss) from operations (4,569 ) 327 Other income (expense): Interest income 2 8 Other expense, net (737 ) (600 ) Change in fair value of financial instruments (162 ) 1,221 Total other income (expense), net (897 ) 629 Income (loss) before income tax expense (5,466 ) 956 Income tax expense 1 - Net income (loss) (5,465 ) 956 Convertible and redeemable preferred stock deemed dividends (20 ) (3 ) Net income (loss) attributable to common stockholders $ (5,485 ) $ 953 Net income (loss) per share attributable to common stockholders: Basic $ (0.04 ) $ 0.01 Diluted $ (0.04 ) $ 0.00 Weighted-average shares used to compute net income (loss) per share attributable to common shareholders: Basic 133,246,864 118,164,046 Diluted 133,246,864 6,155,035,291 Contacts Connect with Us ir@evofem.com media@evofem.com

Physician-curated kit combining antibiotics, trauma & first-aid supplies, 30-day food, and water filtration in one ruggedized case. Rx and non-Rx versions. Preparedness shouldn’t mean piecing together kits from a dozen different vendors and hoping it all fits in a closet.” — , said Aaron Asay, PA-C, DMSc DRAPER, UT, UNITED STATES, April 29, 2026 / EINPresswire.com / -- Jase Medical, the physician-led emergency preparedness company, today announced the launch of Bunker in a Box, a comprehensive, physician-curated readiness system designed to keep individuals and families equipped for the unexpected — from natural disasters and grid-down events to extended supply-chain disruptions and medical emergencies far from a hospital or pharmacy. Built around a heavy-duty, wheeled hard case, Bunker in a Box consolidates the four pillars of emergency self-reliance: medication, first aid, food, and clean water, into a single, organized, grab-and-go solution. The system is available in two configurations: Bunker in a Box Rx — includes Jase’s signature physician-prescribed antibiotic and medication kit (the JaseCase + MedDeck) for households that want prescription coverage built in. Bunker in a Box (non-Rx) — delivers the same trauma, first-aid, food, and water capabilities for customers who prefer to source prescription medications separately. “Preparedness shouldn’t mean piecing together kits from a dozen different vendors and hoping it all fits in a closet,” said Aaron Asay, PA-C, DMSc of Jase Medical. “Bunker in a Box was engineered by physicians and emergency-preparedness specialists to give families a single, trusted system, ready when it matters most, and built around the same clinical rigor that defines everything we do.” What’s Inside the Bunker in a Box Each Bunker in a Box is a complete preparedness system covering trauma and first-aid supplies, emergency food, and clean water, with prescription medications included in the Rx configuration. Every kit is physician-curated for a specific purpose: JaseCase + MedDeck (Rx version): A physician-prescribed antibiotic and medication kit built to treat 80+ infections and medical scenarios when a doctor or pharmacy isn’t accessible. The base kit contains 10 core prescription medications — including amoxicillin-clavulanate, azithromycin, ciprofloxacin, doxycycline, metronidazole, ondansetron, celecoxib, triamcinolone ointment, and methylprednisolone — paired with the MedDeck, a portable set of illustrated instruction cards that walk users through how and when to use each medication in plain language. Optional add-on categories include respiratory/allergy, anti-parasitics, antivirals, steroids/anti-inflammatories, topicals, and OTC supplements. JaseAid: The everyday-carry essential first-aid kit, with bandages, topicals, antiseptics, mini wound-closure tools, dressings, skin-care supplies, sprain and fracture supplies, and an OTC pill pack — designed for cuts, burns, bites, minor sprains, and other common medical scenarios. JaseTrauma: An intensive trauma kit for life-threatening emergencies, including an ETQ tourniquet, Slishman wrap, hemostatic gauze, chest seal, nasopharyngeal airway, compression bandage, sterile abdominal pad, eye shield, large trauma shears, and emergency blanket. Stored inside the JaseMedic bag for rapid access. JaseMedic: A comprehensive, heavy-duty home medical kit equipped for real-world crises — advanced wound care, splints and immobilization, PPE, diagnostic instruments (stethoscope, pulse oximeter, otoscope, digital thermometer), a dental repair kit, and a 9-item OTC pill pack. JasePantry: A 30-day emergency food supply engineered for nutrition, not just calories. Each pantry delivers 2,100 calories and 57 grams of protein per day across 400 servings (63,400 total calories), packaged in oxygen-free Mylar for a 25-year shelf life. Made in the USA with FDA-reviewed ingredients, just-add-water preparation, and a 13-item menu including hearty potato stew, savory beans & rice, buttery herb pasta, brown sugar oatmeal, and an electrolyte drink mix. AquaBrick Water Filter System: A field-proven, BPA-free, food-grade water storage and filtration unit holding 3 gallons per brick, with an integrated DuraFlo filter that removes 99.99999% of bacteria, protozoa, and viruses from tap, stream, or rain water. Stackable for efficient storage and rated for 700 gallons per filter. Emergency Reference Guide: An at-a-glance worksheet for documenting emergency contacts, medical notes, household evacuation plans, and a 6–12-month expiration checklist for kit contents. Engineered for the Unexpected Every component of Bunker in a Box is curated by licensed physicians and designed to function as one cohesive system. The wheeled hard case keeps contents protected, portable, and organized — ready to grab during an evacuation or staged in a basement, garage, or emergency closet. Suggested placement diagrams and field-care educational cards are included throughout to help users locate the right supplies under pressure. “Most preparedness products are sold piecemeal, and families end up with overlapping gear and critical gaps,” added Aaron. “We built Bunker in a Box so that on day one a family is covered across the four critical domains — and on day 30, they still have clean water, real food, and the medical supplies to handle what comes.” Availability Bunker in a Box and Bunker in a Box Rx are available now at https://jase.com/ : Bunker in a Box (non-Rx): https://jase.com/products/bunker-in-a-box Bunker in a Box Rx: https://jase.com/products/bunker-in-a-box JasePlus ™ members receive automatic discounts on Bunker in a Box and on replenishments, plus white-glove restocking support and access to PocketParamedic™, Jase’s on-demand guidance tool for stressful moments. About Jase Medical Founded in 2021 and headquartered in Draper, Utah, Jase Medical empowers individuals and families to be medically and practically prepared for the unexpected. With support from leading medical experts and preparedness specialists from Boston Children’s Hospital, Columbia University, Harvard Medical School, Mayo Clinic, Stanford University, and the University of Utah, Jase delivers physician-curated solutions for emergency readiness — from prescription antibiotic kits to trauma supplies, long-shelf-life food, and clean water. Jase Medical was named to MountainWest Capital Network’s 2025 Utah 100 Emerging Elite, recognizing the state’s fastest-growing companies. Learn more at https://jase.com/ John Thuet Jase Medical +1 888-522-6912 email us here Visit us on social media: Instagram Facebook YouTube Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.